|Bid||90.00 x 800|
|Ask||119.87 x 800|
|Day's Range||106.00 - 112.34|
|52 Week Range||34.39 - 112.34|
|Beta (5Y Monthly)||2.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||114.54|
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and Mirati Therapeutics (MRTX), a clinical-stage targeted oncology company, today announced preliminary data from an ongoing Phase 1b trial of investigational anti-PD-1 antibody tislelizumab in combination with investigational tyrosine kinase inhibitor sitravatinib in patients with platinum-resistant ovarian cancer, which demonstrated antitumor activity and was generally well tolerated. Results from the Phase 1b clinical trial were presented at the 2019 European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress on December 13, 2019 in Geneva, Switzerland.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Mirati Therapeutics, Inc. (NASDAQ:MRTX). Mirati Therapeutics, Inc. (NASDAQ:MRTX) shareholders have […]
SAN DIEGO, Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in metastatic urothelial cancer (mUC) patients with documented progression on a platinum-chemotherapy and checkpoint inhibitor. Preliminary results from the ongoing Phase 1 study of neoadjuvant sitravatinib combined with nivolumab in patients with resectable squamous cell carcinoma of the oral cavity (SNOW trial) were also presented in a poster session. "Sitravatinib is a spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases, including TAM family receptors (TYRO3, Axl, Mer), that has the potential to increase responsiveness in patients whose tumors are resistant to checkpoint inhibitors.
Mirati (MRTX) delivered earnings and revenue surprises of -8.66% and 97.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, ...
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive ...
- Preliminary Clinical Activity and Favorable Safety Profile Support Dose Expansion - Maximum Tolerated Dose Has Not Yet Been Established - MRTX849 Data Published in 'Cancer Discovery', in Coordination ...
An experimental drug from Mirati Therapeutics Inc that targets a specific genetic mutation significantly reduced tumor size in 40% of patients with advanced lung and colorectal cancer so far evaluated in a small, early-stage trial, researchers said on Monday. Investors have been keen to see how Mirati's data stacks up against results for a similar drug, AMG510, under development by Amgen Inc. Both target a mutated form of a gene known as KRAS that occurs in around 13% of non-small cell lung cancer cases, 3-5% of colorectal cancers and up to 2% of other solid tumor cancers. Out of 17 patients enrolled in the Phase 1 trial of Mirati's oral drug MRTX849, 12 have been evaluated, including six with lung cancer and four with colorectal cancer.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
SAN DIEGO , Oct. 23, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that the Company will have two presentations at the Society for ...
SAN DIEGO , Oct. 17, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present pre-clinical data and initial clinical data ...
Mirati Therapeutics Inc (NASDAQ: MRTX ), a thinly traded, smid-cap oncology biotech, is on investors' radars ahead of upcoming conference presentations and data readouts. Mirati is expected to make a late-breaking presentation ...
Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
President & CEO of Mirati Therapeutics Inc (30-Year Financial, Insider Trades) Charles M Baum (insider trades) sold 51,810 shares of MRTX on 08/22/2019 at an average price of $86.22 a share. Continue reading...
Today we will run through one way of estimating the intrinsic value of Mirati Therapeutics, Inc. (NASDAQ:MRTX) by...
SAN DIEGO, Aug. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, announced the appointment of Jenny Gizzi as Vice President, Human Resources, reporting directly to Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer. In her role, Ms. Gizzi will be responsible for all aspects of the Company's human resources operations and strategy, including overseeing the planning, development, implementation and administration of Mirati's human resources programs. This critical perspective will help us maintain our dynamic culture as we further advance our programs and continue our growth into a premier targeted oncology company," said Dr. Charles Baum.
SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019 ...
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.